Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Asset Writedowns and Impairment: 2014-2023

Historic Asset Writedowns and Impairment for Heron Therapeutics (HRTX) over the last 7 years, with Dec 2023 value amounting to $617,000.

  • Heron Therapeutics' Asset Writedowns and Impairment rose 437.66% to $828,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $4.4 million, marking a year-over-year increase of 716.05%. This contributed to the annual value of $617,000 for FY2023, which is 195.22% up from last year.
  • Heron Therapeutics' Asset Writedowns and Impairment amounted to $617,000 in FY2023, which was up 195.22% from $209,000 recorded in FY2022.
  • Heron Therapeutics' Asset Writedowns and Impairment's 5-year high stood at $847,000 during FY2020, with a 5-year trough of $107,000 in FY2019.
  • In the last 3 years, Heron Therapeutics' Asset Writedowns and Impairment had a median value of $478,000 in 2021 and averaged $434,667.
  • Per our database at Business Quant, Heron Therapeutics' Asset Writedowns and Impairment soared by 691.59% in 2020 and then crashed by 56.28% in 2022.
  • Yearly analysis of 5 years shows Heron Therapeutics' Asset Writedowns and Impairment stood at $107,000 in 2019, then skyrocketed by 691.59% to $847,000 in 2020, then slumped by 43.57% to $478,000 in 2021, then tumbled by 56.28% to $209,000 in 2022, then spiked by 195.22% to $617,000 in 2023.